medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2020, Number S1

<< Back Next >>

Revista Cubana de Salud Pública 2020; 46 (S1)

COVID-19 in Santiago de Cuba province from an implicative statistical analysis

Sagaró CNM, Zamora ML, Valdés GLE, Bergues CLE, Rodríguez VA, Morandeira PHM

Language: Spanish
References: 30
Page: 1-21
PDF size: 1262.08 Kb.


ABSTRACT

Objective: To describe the behaviour of COVID-19 confirmed cases from Santiago de Cuba province between March and April, 2020.
Methods: It was carried out a cross-sectional, observational descriptive study taking as studied population 49 COVID-19 positive cases in Santiago de Cuba province between March and April, 2020. There were selected clinic and epidemiologic variables. As statistical technique it was applied the implicative statistical analysis with its three forms: similarity, cohesive, and implicative.
Results: It was obtained a set of all the relations among the studied variables in a graphic way, being highlighted the differences among both sexes since the females were related to the asymptomatic category and the males to symptomatic, seriously ill and deceased categories; while older adults were related with the higher amount of personal pathological background and the deceased ones, and young adults were related to the backgrounds and respiratory system’s symptoms.
Conclusions: This study allows to visualize, as a distinctive feature of COVID-19 cases´ behaviour in Santiago de Cuba province, that the highest risk sub-group is the one of male older adults with underlying diseases, mainly arterial hypertension, which is similar to what is happening in other regions of the world.


REFERENCES

  1. WHO. Coronavirus Disease (COVID-19) Dashboard. CEST. Ginebra: WHO; 2020 [actualizado 22/05/2020; acceso 22/05/2020]. Disponible en: https://covid19.who.int/

  2. Ministerio de Salud Pública. Coronavirus en Cuba. Información Oficial del Minsap Parte del cierre del día 20 de mayo a las 12 de la noche. La Habana: Minsap; 2020 [acceso 22/05/2020] Disponible en: https://salud.msp.gob.cu

  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2019. Lancet. 2020 [acceso 10/05/2020];395(10223):497-506. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30183-5

  4. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020 [acceso 10/05/2020];3(4). Disponible en: https://jamanetwork.com/journals/jamane-tworkopen/fullarticle/2764293

  5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 [acceso 10/05/2020];3(4). Disponible en: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764293#editorial-comment-tab

  6. Sagaró Del Campo N, Zamora Matamoros L. Análisis estadístico implicativo versus Regresión logística binaria para el estudio de la causalidad en salud. MULTIMED. 2019 [acceso 22/05/2020];23(6):1416-40. Disponible en: http://www.revmultimed.sld.cu/index.php/mtm/article/view/1435

  7. Sagaró Del Campo NM, Zamora Matamoros L. ¿Por qué emplear el análisis estadístico implicativo en los estudios de causalidad en salud?. RCIM. 2019;11(1):88-103. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1684-18592019000100088&script=sci_arttext&tlng=en

  8. Li J, Zhang Y, Wang F, Liu B, Li H, Tang G, et al. Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID-19) and severe condition. medRxiv preprint. 2020. DOI: 10.1101/2020.02.27.20027524

  9. Wei X, Xiao YT, Wang J, Chen R, Zhang W, Yang Y, et al. Sex Differences in Severity and Mortality Among Patients with COVID-19: Evidence from Pooled Literature Analysis and Insights from Integrated Bioinformatic Analysis. arXiv preprint. 2020 DOI: 10.1101/2020.02.27.20027524

  10. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol. 2004;159(3):229-31. DOI: 10.1093/aje/kwh056

  11. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016 [acceso 10/05/2020];16(10):626-38. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27546235

  12. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol. 2017 [acceso 22/05/2020];198(10):4046-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28373583

  13. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. [publicado en línea antes de la impresión, 20 mar 2020]. Rev Clin Esp. 2020;S0014-2565(20)30092-8. DOI: 10.1016/j.rce.2020.03.001

  14. Promislow DE. A geroscience perspective on COVID-19 mortality. The Journals of Gerontology. 2020;Series A, glaa094. DOI: 10.1093/gerona/glaa094

  15. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020 [acceso 10/05/2020];323(18):1775-76. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2763667

  16. Mills JP, Kaye KS, Mody L. COVID-19 in older adults: clinical, psychosocial, and public health considerations. JCI Insight. 2020;5(10):e139292. DOI: 10.1172/jci.insight.139292

  17. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. DOI: 10.1001/jamainternmed.2020.0994

  18. Márquez EJ, Chung C-h, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et al. Sexual-dimorphism in human immune system aging. Nature communications. 2020 [acceso 22/05/2020];11:1-17. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32029736

  19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 [acceso 10/05/2020];395:1054-62. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186205/

  20. Bos JM, Hebl VB, Oberg AL, Sun Z, Herman DS, Teekakirikul P, et al. Marked Up-Regulation of ACE2 in Hearts of Patients with Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19. Mayo Clin Proc. 2020 [acceso 02/05/2020];95. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186205/

  21. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):pii=2000180. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180

  22. Liu Y, Centre for Mathematical Modelling of Infectious Diseases nCoV Working Group, Funk S, Flasche S. The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019. Wellcome Open Res. 2020;5:58. DOI: 10.12688/wellcomeopenres.15788.1

  23. Rodríguez Labrada R, Vazquez-Mojena Y, Velázquez-Pérez L. Transmisión asintomática y presintomática del SARS-CoV-2: la cara oculta de la COVID-19. Anales de la Academia de Ciencias de Cuba. 2020 [acceso 10/05/2020];10(2). Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/770

  24. Ruocco G, Feola M, Palazzuoli A. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases. 2020 [acceso 10/05/2020];95:373-5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180155/

  25. Minsap. Dirección de Registros Médicos y Estadísticas de Salud. Anuario de Salud 2019. La Habana: Minsap; 2020 [acceso 22/05/2020]:97. Disponible en https://salud.msp.gob.cu/?tag=anuario-estadistico-de-salud

  26. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:1-10. DOI: 10.1016/j.cell.2020.02.052

  27. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virology. 2020;94(7). DOI: 10.1128/JVI.00127-20

  28. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):E21. DOI: 10.1016/S2213-2600(20)30116-8

  29. Giralt-Herrera A, Rojas-Velázquez JM, Leiva-Enríquez J. Relación entre COVID-19 e Hipertensión Arterial. Rev haban cienc méd. 2020 [acceso 22/05/2020];19(2):e3246. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3246

  30. Rachadell J, Vareda R, Pinto FSA, Duarte R, Neto S, Oliveira Henriques S, Vaz Carneiro A. O tratamento previo com inhibidores da enzima de conversão da angiotensina, e/ou bloqueadores dos receptores da angiotensina, e/ou betabloqueadores, e/ou antagonistas dos canais de cálcio e/ou diuréticos tiazídicos não apresenta risco acrescido naCovid-19. En: Instituto de Saúde Baseada na Evidência. Cochrane Portugal Newsletter. 2020-n19; 4 may. 2020 [acceso 10/05/2020] Disponible en: https://portugal.cochrane.org/sites/portugal.cochrane.org/files/public/uploads/newsletter_19_isbe_20200504.pdf




2020     |     www.medigraphic.com